Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02415608 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
A Phase 2 study, sponsored by Jason Robert Gotlib.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02415608 is a Phase 2 study that was terminated before completion, run by Jason Robert Gotlib. The registered enrollment target is 4 participants.
The verdict
NCT02415608, a Phase 2 study, was terminated before completion, sponsored by Jason Robert Gotlib.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with treatment (advanced). Systemic mastocytosis is a disease in which too many mast cells (a type of immune system cell) are found throughout the body. Mast cells give off chemicals such as histamine that can cause flushing (a hot, red face), itching, abdominal cramps, muscle pain, nausea, vomiting, diarrhea, low blood pressure, and shock. Ibrutinib may stop the growth of mast cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02415608
The ClinicalTrials.gov registry entry for NCT02415608 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jason Robert Gotlib, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibrutinib is the first listed.
NCT02415608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02415608 about?
NCT02415608 is a clinical study titled "Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis". This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with treatment (advanced). Systemic mastocytosis is a disease in which too ma...
What is the current status of trial NCT02415608?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-03. Estimated completion is 2017-06-14.
What interventions are being tested in trial NCT02415608?
The interventions under investigation include: Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02415608?
This trial is sponsored by Jason Robert Gotlib, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.